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Abstract
Acquired von Willebrand syndrome (AVWS) associated with severe aortic stenosis (AS) has been frequently subclassified into a
subtype 2A based on the deficiency of high-molecular-weight (HMW) multimers as it is seen in inherited von Willebrand disease
(VWD) type 2A. However, the multimeric phenotype of VWD type 2A does not only include an HMW deficiency but also a
decrease in intermediate-molecular-weight (IMW) multimers and an abnormal inner triplet band pattern. These additional
characteristics have not been evaluated in AVWS associated with severe AS. Therefore, we recruited N ¼ 31 consecutive
patients with severe AS and performed a high-resolution Western blot with densitometrical band quantification to characterize
the vonWillebrand factor (VWF) multimeric structure and reevaluate the AVWS subtype classification. Study patients showed an
isolated HMW VWF multimer deficiency without additional abnormalities of the IMW portions and the inner triplet structure in
65%. In conclusion, the multimeric pattern of AVWS associated with severe AS does neither resemble that seen in AVWS type 2A
nor that seen in inherited VWD type 2A. Therefore, a subclassification into a type 2A should not be used.
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Background
Acquired von Willebrand syndrome (AVWS) type 2 has been
frequently found in patients with severe aortic stenosis (AS)
with a prevalence up to 80%.1 In these patients, AVWS is
characterized by proteolytic loss of high-molecular-weight
(HMW) multimers of von Willebrand factor (VWF) due to a
high shear force.2,3 Passage through a stenosed aortic valve
induces a structural molecular change in VWF, which makes
the molecule sensitive to proteolytic cleavage by the metallo-
protease ADAMTS13 with subsequent degradation of HMW
multimers.4,5 High-molecular-weight multimers represent the
hemostatically most active form of VWF, and thus, its defi-
ciency results in bleeding complications ranging from epistaxis
to gastrointestinal hemorrhage. Acquired von Willebrand syn-
drome and associated primary hemostasis abnormalities are
corrected by surgical6,7 or interventional8 valve replacement
that supports this mechanistic concept.
It has been suggested that the abnormal VWF multimeric
structure in the setting of AS resembles that of an inherited
type 2A von Willebrand disease (VWD),2 which has led to the
frequent subclassification into AVWS type 2A in various
studies.9-14 Type 2A VWD is characterized by the deficiency
of HMW multimers, the reduction in intermediate molecular
weight (IMW) multimers and an abnormal triplet band pattern
of the lower molecular weight multimers.15-18 Neither IMW
multimers nor the multimeric triplet configuration has been
evaluated in patients with AVWS associated with AS, which
could have led to a misclassification in previous studies.
Therefore, in our present project, we aimed to analyze the
complete VWF multimeric structure in patients with severe AS
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including the low- and intermediate-molecular-weight multi-
mer portions and the triplet structure.
Materials and Methods
Laboratory Analysis
Blood sampling was performed after echocardiographic diag-
nosis of severe AS as described below. von Willebrand factor
antigen (VWF:Ag), VWF activity (VWF:GPIbM), and factor
VIII coagulation activity (FVIII:C) were determined using
photo-optical measurements (Healthcare Diagnostics, Sie-
mens, Erlangen, Germany) and were abbreviated based on the
approved nomenclature.19 von Willebrand factor multimeric
structure analysis was assessed using a Western blot according
to the protocol of Ott et al.15 Briefly, VWF multimeric bands
were electrophoretically separated using a low-resolving (1%)
and a high-resolving (2%) agarose gel. For immunolocaliza-
tion, we used a polyclonal rabbit anti-VWF (DAKO, Glostrup,
Denmark) as the primary antibody and a Cy5-labeled ECL Plex
goat anti-rabbit IgG (GE Healthcare Life Sciences, Marlbor-
ough, Massachusetts) as the secondary antibody. von Willeb-
rand factor multimeric bands were densitometrically quantified
using CCD camera and Image Quant LAS 4000 software (GE
Healthcare Life Sciences). A normal VWF multimeric pattern
consists of low-molecular-weight (LMW, bands 1-3),
intermediate-molecular-weight (IMW, bands 4-13), and high-
molecular-weight (HMW, bands >13) bands. Acquired von
Willebrand syndrome type 2 was defined by the loss of HMW
bands compared to normal plasma.
A decrease in HMW and IMW VWF multimers accompa-
nied by an abnormal triplet band pattern was regarded indica-
tive of an AVWS “type 2A.” The resulting VWF multimer
structure was compared to the multimer pattern of previously
diagnosed AVWS type 2A and inherited type 2A VWD of our
institutional database.
von Willebrand factor multimeric band pattern was ana-
lyzed by experienced laboratory physicians blinded to echocar-
diographic and baseline patient characteristics. Our institution
is an experienced center for VWF multimer analysis with more
than 1400 VWF Western blots every year.
Study Patients
Consecutive patients with the diagnosis of severe AS (N ¼ 31)
were prospectively enrolled after providing written informed
consent in accordance with the Declaration of Helsinki under a
protocol reviewed by the local Ethics Committee. Patients with
a history of surgical or interventional valve replacement and
patients with other significant valve diseases, acute decompen-
sated heart failure, or liver cirrhosis were excluded. Severe AS
was defined as an echocardiographic peak aortic jet velocity
4m/s, a mean transvalvular pressure gradient 40 mm Hg,
and an aortic valve area (AVA; calculated by continuity equa-
tion) <1 cm2. The stenosis-induced shear stress that impacts
on vWF was calculated as 4m Vm/r (m ¼ blood viscosity
[estimated as 0.035 poise]; Vm ¼ mean transvalvular blood
velocity; r ¼ radius of the stenosis, which is calculated:
[AVA/p]1/2). Bleeding symptoms in the previous 12 months
were evaluated using a standardized screening questionnaire
adapted from those by Rapaport.20
Statistics
The study was designed as a monocentric hypothesis-
generating study. All P values are descriptive and presented
to 3 decimal values. Categorical data are presented using
counts and percentages, and Fisher exact test (2  2 tables)
was calculated. Continuous measurements are presented using
Table 1. Baseline patient characteristics including clinical, echocar-
diographic and laboratory data.
N ¼ 31
Baseline patient characteristics
Age, mean + SD, years 79 + 8
Male gender (%) 21/31 (68%)
BMI, mean kg/m2 26 + 6
Height, mean+ SD, cm 166 + 9
Weight, mean + SD, kg 72.6 + 14.9
Current smoking (%) 19.4
Diabetes (%) 29.0
Coronary artery disease (%) 51.6
Echocardiographic data
Peak aortic jet velocity, mean + SD, m/s 4.7 + 0.5
Max./Mean aortic gradient, mean+ SD, mm Hg 90+ 17/ 56+ 10
AVA, mean + SD, cm2 0.64 + 0.14
Systolic ejection fraction (%) 60 + 9
Intraventricular septum thickness, mean+ SD,
mm
1.7 + 0.2
LVEDD, mean + SD, cm 4.9 + 0.7
LVESD, mean+ SD, cm 3.2 + 0.6
Shear stress, mean + SD, dyn/cm2 107 + 12
Bleeding history (previous 12 months)
GI bleeding (%) 8/31 (25.8%)
Gingivorrhagia and/or epistaxis (%) 3/31 (9.7%)
Spontaneous hematoma (%) 6/31 (19.4%)
Hematuria (%) 3/31 (9.7%)
Laboratory data
Hemoglobin, mean + SD, g/dL 11.7 + 2.0
Thrombocyte count, mean + SD, G/L 228 + 71
aPTT, mean + SD, seconds 28.8 + 7.8
C-reactive protein, mean+ SD, mg/dL 1.2 + 0.9
proBNP, mean+ SD, pg/mL 3427 + 5112
VWF:Ag (%) 198 + 92
VWF:GPIbM (%) 164 + 66
FVIII:C (%) 177 + 52
HMW multimer deficiency (%) 20/31 (65%)
IMW multimer deficiency (%) 0/31 (0%)
LMW multimer deficiency (%) 0/31 (0%)
Abnormal triplet structure (%) 0/31 (0%)
Abbreviations: aPTT, activated partial thromboplastin time; AVA, aortic valve
area; FVIII:C, factor VIII coagulation activity; HMW, high molecular weight; IMW,
intermediate molecular weight; LMW, low molecular weight; LVEDD, left ven-
tricular end diastolic diameter; LVESD, left ventricular end systolic diameter;
pro-BNP, pro-brain natriuretic peptide; SD, standard deviation; VWF:Ag, von
Willebrand factor antigen; VWF:GPIbM, von Willebrand factor activity.
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arithmetic mean and standard deviation (SD). For the compar-
ison of 2 independent groups, if normality was assumed, the
2-sample t test was used. If normality was not assumed, the
exact Mann-Whitney U test was used.
Results
Patient baseline characteristics and echocardiographic findings
are shown in Table 1. Study patients had a mean age of 79+
8 years and a mean body mass index (kg/m2) of 26 + 6, and
68% were male gender. The most frequent clinical symptoms
were chest pain (51.6%) and dyspnea (New York Heart Asso-
ciation [NYHA] I [no shortness of breath in ordinary physical
activity]:4/31 [12.9%], NYHA II [mild shortness of breath]: 14/
31 [45.2%], NYHA III [moderate shortness of breath]: 10/31
[32.2%], NYHA IV [shortness of breath at rest]: 3/31 [9.7%]).
Bleeding episodes in the previous 12 months were reported in
12 (38.7%) out of 31 patients (gingivorrhagia/epistaxis: 9.7%,
spontaneous hematoma: 19.4%, prolonged bleeding after sur-
gery: 0%, gastro-intestinal hemorrhage: 25.8%, cerebral
hemorrhage: 0%, menorrhagia: 0%, and hematuria: 9.7% of all
patients). A total of 54.8% of all patients were on antiaggrega-
tory and 25.8% on anticoagulant treatment at the time of bleed-
ing symptom evaluation. All patients were diagnosed with
severe AS with a peak aortic jet velocity of 4.7 + 0.5 m/s
and a mean transvalvular gradient of 56 + 10 mm Hg in the
presence of normal systolic ejection fraction. Considering
hemodynamic findings, comorbidities and clinical status
patient management ranged from conservative treatment (5/
31; 16.1%) to surgical valve replacement (11/31; 35.5%) or
TAVR (transcatheter aortic valve replacement (14/31;
45.2%). One patient died before projected surgical intervention.
Laboratory findings including results of VWF:Ag,
VWF:GPIbM, FVIII:C, and VWFmultimer analyses are shown
in Tables 1 and 2. Patients had a mean hemoglobin level of
11.7 + 2.0 g/dL, mean thrombocyte count of 228 + 71 G/L,
and a mean activated partial thromboplastin time (aPTT) of
28.8 + 7.8 seconds. Low-resolution gel electrophoresis
revealed an HMW multimer deficiency without an additional
decrease in LMW or IMW portions in 65% of all patients
(Table 1 and Figure 1). High-resolution gel analysis showed
a normal inner multimeric triplet structure in all study patients
(Figure 2). Among patients with reported bleeding episodes,
91.7% had an abnormal multimeric pattern, whereas only 8.3%
had a normal multimeric structure. Noteworthily, none of the
blood samples showed a multimeric pattern identical to AVWS
type 2A or VWD type 2A (Figures 1 and 2). Results of assays
for VWF:Ag and VWF:GPIbM were in the range of normal in
most patients (83.9%), and VWF:GPIbM/VWF:Ag ratio <0.7
was detectable in only 20.0% of all patients with HMW
Table 2. Comparison of baseline characteristics between patients with versus without abnormal VWF multimer structure.
Abnormal Multimeric
Structure (n ¼ 20)
Normal Multimeric
Structure (n ¼ 11) P Value
Patient characteristics
Age, mean + SD, years 81 + 5 76 + 11 .238
Male gender (%) 14/20 (70%) 7/11 (64%) 1.000
BMI, mean + SD, kg/m2 27 + 6 26 + 4 .645
Echocardiographic data
Peak aortic jet velocity, mean + SD, m/s 4.8+ 0.5 4.6 + 0.4 .274
Peak aortic gradient, mean+ SD, mm Hg 93 + 18 86 + 15 .301
Mean aortic gradient, mean+ SD, mmHg 57 + 11 54 + 9 .574
AVA, mean+ SD, cm2 0.65 + 0.13 0.69 + 0.18 .521
Systolic ejection fraction (%) 59 + 10 61 + 4 .910
Shear stress, mean + SD, dyn/cm2 107 + 13 106 + 14 .961
Laboratory characteristics
Hemoglobin, mean + SD, g/dL 11.3 + 2.2 12.5 + 1.5 .098
Thrombocyte count, mean + SD, G/L 233 + 83 219 + 42 .620
aPTT, mean+ SD, sec 25.4 + 1.4 30.2 + 8.9 .068
C-reactive protein, mean + SD, mg/dL 1.2+ 1.0 1.2 + 0.8 .782
proBNP, mean+ SD, pg/mL 4500 + 5930 1477 + 2259 .043
VWF:Ag (%) 176 + 74 210 + 100 .470
VWF:GPIbM (%) 160 + 59 166 + 72 .813
FVIII:C (%) 187 + 50 157 + 52 .119
VWF:GPIbM/VWF:Ag ratio 0.81 + 0.12 1.01 + 0.20 .001
Bleeding history
GI bleeding (%) 7/20 (35%) 1/11 (9.1%) .202
Gingivorrhagia and epistaxis (%) 3/20 (15%) 0/11 (0%) .535
Spontaneous hematoma (%) 6/20 (30%) 0/11 (0%) .065
Hematuria (%) 2/20 (10%) 1/11 (9.1%) 1.000
Abbreviations: aPTT, activated partial thromboplastin time; AVA, aortic valve area; BMI, body mass index; FVIII:C, factor VIII coagulation activity; GI, gastro-
intestinal; proBNP, pro-brain natriuretic peptide; SD, standard deviation; VWF:Ag, von Willebrand factor antigen; VWF:GPIbM, von Willebrand factor activity.
Note: The bold numbers are below the significance level p < 0.05.
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Figure 1. Illustration of VWF multimer low-resolution gel electrophoresis (left side of the panel) and densitometrical band quantification
(right side of the panel) of 4 individuals in comparison with a reference standard. Top row (patient A with severe AS) shows a normal VWF
multimer electrophoresis band pattern with a normal densitometrical quantification of low- (bands 1-3), intermediate- (bands 4-13), and high-
(bands >13) molecular-weight VWF multimers. The middle top row (patient B with severe AS) depicts an isolated deficiency of high-molecular-
weight multimers both in the electrophoresis and in the densitometrical quantification in comparison with a reference standard. The middle
bottom row (patient C with myeloproliferative syndrome) illustrates the electrophoresis and densitometrical pattern of a previously diagnosed
typical AVWS type 2A characterized by a decrease in the high- and intermediate-molecular-weight multimers. The bottom row (patient D)
shows intermediate- and high-molecular-weight VWF multimer deficiency of a young child with previously diagnosed VWD type 2A. The VWF
multimer structure of patient B does not resemble the multimer pattern as it is seen in patient C and D. AS denotes aortic stenosis; AVWS,
acquired von Willebrand syndrome; VWF, von Willebrand factor.
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multimer deficiency, and thus, only the multimer analysis
yielded the correct diagnosis. Differences in patient character-
istics, echocardiographic, and laboratory findings between
patients with and without AVWS multimeric pattern are shown
in Table 2.
Discussion
von Willebrand disease is the most common inherited bleeding
disorder and is categorized into a partial quantitative (type 1), a
qualitative (type 2) and a total quantitative (virtually complete
deficiency; type 3) subtype according to the revised classifica-
tion by the VWF subcommittee of the ISTH published in 2006.21
Although laboratory tests (such as the measurement of
plasma concentration of VWF antigen, VWF binding activity,
FVIII:C, and VWF:GPIbM/VWF:Ag ratio) represent the
diagnostic cornerstone of VWD, these assays are frequently
unspecific in AVWS. Therefore, VWF multimer analysis
using protein electrophoresis remains the gold standard for
AVWS diagnosis. Although, historically, AVWS has not been
further subclassified, the similarity of the multimeric band
pattern that is found in VWD type 2 and AVWS in severe
AS has led to an analogous subclassification. von Willebrand
disease type 2 is further subcategorized into type 2A, 2B, 2N,
and 2M. von Willebrand disease type 2A and type 2B are the
only subtypes to feature HMW multimer deficiency and can
be distinguished using multimeric structure and a ristocetin-
induced platelet aggregation (RIPA) assay. Although VWD
type 2A is characterized by a reduction in both HMW and
IMW multimers, an abnormal triplet structure, and a hypoac-
tive RIPA, VWD type 2B shows an isolated HMW multimer
deficiency, preserved triplet structure, and hyperactive RIPA.
The RIPA assay is frequently not reliable in AVWS, thus
VWF multimer structure analysis remains the gold standard
to diagnose AVWS.
Acquired von Willebrand syndrome in the setting of AS has
become an extensively studied topic in recent years and has
been frequently subcategorized into type 2A, according to the
VWF multimeric band phenotype. Our literature research
revealed that neither IMW multimers nor the multimer triplet
structure has been evaluated in the setting of AS. Hence, we
supposed that AVWS could have been previously misclassified.
Consequently, we recruited 31 consecutive patients with
severe AS, evaluated bleeding symptoms via questionnaire,
and analyzed the VWF multimeric structure. The prevalence
of VWF multimer abnormalities was high, whereas a bleeding
history was present in only the minority of patients, indicating
a “hemostatic rescue mechanism,” which has been recently
proposed.1 Besides a slight difference in pro-brain natriuretic
peptide levels and VWF:GPIbM/VWF:Ag ratio, all other
laboratory parameters were comparable between patients with
and without HMW VWF multimer deficiency (Table 2).
Results of VWF:Ag, VWF:GPIbM, (VWF:GPIbM/
VWF:Ag ratio), and FVIII:C were unspecific in patients with
an abnormal multimeric phenotype, which underscores the
importance of gel electrophoresis for the diagnosis of AVWS.
Multimeric band pattern analysis revealed a preserved triplet
structure and normal band distribution and density in the IMW
portions in all patients. A deficiency in the HMW portions
accounted exclusively for the abnormal band pattern and,
therefore, did neither resemble the multimer band pattern seen
in AVWS type 2A nor that seen in VWD type 2A.
Noteworthily, in our study, the bleeding phenotype in
patients with VWF multimer abnormalities appeared to be less
common than expected, which is in accordance with previous
findings.1 We suppose that the hemostatic capacity is still suf-
ficient in patients with HMW VWF multimer deficiency under
steady state conditions, whereas external influences (ie,
trauma, surgery, and infection) might result in bleeding com-
plications. It is unclear whether an additional decrease of IMW
multimers in the setting of AS would have resulted in an
increased bleeding prevalence compared to the present isolated
HMW multimer deficiency.
There is a demand for a standardization of VWF multimer
Western blot results in order to improve the diagnostic value,
comparability, and reproducibility of the test and to avoid mis-
classifications. To achieve a test harmonization, a required
minimum number of multimer bands on agarose gels and a
clear definition for multimer subcategorization into the LMW,
IMW, and HMW subset is necessary. In our present experi-
ments, VWF multimer gel electrophoresis contained at least 19
bands, displayed the multimer triplet structure in the high-
Figure 2. Illustration of the inner triplet sub-band structure of VWF
multimers. Plasma samples of a healthy person (left panel), a patient
with severe AS with isolated HMWVWF deficiency (middle panel) and
a patient with previously diagnosed typical AVWS type 2A associated
with myeloproliferative syndrome (right panel) were electrophoreti-
cally separated on an SDS high-resolution (2%) agarose gel. The
characteristic triplet subband structure consisting of 2 satellite (grey
arrows) and 1 main band (black arrow) can be seen in the left and the
middle panel, whereas the right panel shows an abnormal subband
composition (black bold arrow) typical of AVWS type 2A. AVWS
denotes acquired von Willebrand syndrome; SDS, sodium dodecyl
sulfate; VWF, von Willebrand factor.
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resolution gel, and bands 4 to 13 were defined as IMWwhereas
bands >13 were defined as HMW multimers.
Conclusion
Our present study reveals that multimeric pattern of AVWS in
severe AS is not identical to that seen in AVWS type 2A or
VWD type 2A and should not be subclassified as type 2A
anymore. A lack of electrophoresis standardizations might
have contributed to previous misclassifications, and thus, there
is a demand for standardized diagnostic guidelines to avoid
future AVWS misclassifications in clinical practice and
research.
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